

Human T cell glycosylation and implications on immune therapy for cancer

Elie De Bousser, Leander Meuris, Nico Callewaert & Nele Festjens

To cite this article: Elie De Bousser, Leander Meuris, Nico Callewaert & Nele Festjens (2020): Human T cell glycosylation and implications on immune therapy for cancer, Human Vaccines & Immunotherapeutics, DOI: [10.1080/21645515.2020.1730658](https://doi.org/10.1080/21645515.2020.1730658)

To link to this article: <https://doi.org/10.1080/21645515.2020.1730658>



© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.



Published online: 18 Mar 2020.



Submit your article to this journal [↗](#)



Article views: 136







View related articles [↗](#)



View Crossmark data [↗](#)

Human T cell glycosylation and implications on immune therapy for cancer

Elien De Bousser ^{a,b}, Leander Meuris ^{a,b}, Nico Callewaert ^{a,b}, and Nele Festjens ^{a,b}

^aVIB-UGent Center for Medical Biotechnology, Ghent, Belgium; ^bDepartment of Biochemistry and Microbiology, Ghent University, Ghent, Belgium

ABSTRACT

Glycosylation is an important post-translational modification, giving rise to a diverse and abundant repertoire of glycans on the cell surface, collectively known as the glycome. When focusing on immunity, glycans are indispensable in virtually all signaling and cell-cell interactions. More specifically, glycans have been shown to regulate key pathophysiological steps within T cell biology such as T cell development, thymocyte selection, T cell activity and signaling as well as T cell differentiation and proliferation. They are of major importance in determining the interaction of human T cells with tumor cells. In this review, we will describe the role of glycosylation of human T cells in more depth, elaborate on the importance of glycosylation in the interaction of human T cells with tumor cells and discuss the potential of cancer immunotherapies that are based on manipulating the glycome functions at the tumor immune interface.

ARTICLE HISTORY

Received 15 November 2019
Revised 21 January 2020
Accepted 12 February 2020

KEYWORDS

Glycosylation; human T cell; immunotherapy; glycan-binding protein; engineering

Introduction

Mammalian glycosylation

Glycosylation is the enzymatic process that leads to the formation of glycosidic linkages between carbohydrates and other carbohydrates, proteins or lipids. Next to proteolytic cleavage and modification of disulfide bonds, glycosylation is an important post-translational modification that gives rise to a diverse and abundant repertoire of glycans on the cell surface, collectively known as the glycome.^{1–3} Known human glycans are formed almost exclusively from only ten monosaccharide building blocks (L-fucose, D-galactose, N-acetyl-D-galactosamine (GalNAc), N-acetyl-D-glucosamine (GlcNAc), D-glucuronic acid, D-iduronic acid, D-mannose, N-acetylneuraminic acid and D-xylose), which can be modified in particular glycoconjugates with sulfation, phosphorylation or de-acetylation. Through the orchestrated action of a diverse set of glycosyltransferases, glycosidases, glycan phosphorylases and polysaccharide lyases, a large diversity of mammalian glycans is generated. The biosynthesis of glycans is primarily determined by glycosyltransferases, enzymes that use activated sugar nucleotides or dolichol-phosphate bound donors as substrate in the enzymatic formation of glycosidic linkages to initiate, extend and diversify glycan structures. The expression of these glycosyltransferases is often highly regulated in a cell-type specific manner that changes during development, differentiation and activation, implying that changes in the glycome can occur in response to environmental and genetic stimuli.⁴ However, the exact regulation of glycan synthesis is still not completely understood, and this is mainly due to the complexity inherent to the macromolecule itself and its nontemplated mode of biosynthesis.⁵ The latter means that genomic information is not just ‘decoded’ by the ribosome translating the linear DNA code to a linear product, but

that genomic information is ‘translated’ by a combination of transcriptional and membrane transport processes into a specific Golgi configuration.⁶

The most frequently occurring types of mammalian protein glycosylation are N- and mucin type O-linked glycosylation and they lead to a large structural repertoire of glycans present on nearly every secreted and integral membrane protein. N-glycans are relatively bulky structures of which the synthesis starts on a lipid precursor at the cytoplasmic face of the endoplasmic reticulum (ER). After transfer to the ER lumen by an ER-resident flippase and further addition of monosaccharides, the glycan is transferred to nascent polypeptides at the side-chain amide nitrogen on asparagine residues in an N-x-S/T consensus sequence. After playing its role in protein folding quality control, the glycan is trimmed to a high mannose type structure carrying terminal mannoses. After transport from the ER to the Golgi apparatus (GA), the glycan can be further trimmed. At this point, these oligomannose glycans can remain unchanged, but most are subsequently rebuilt into hybrid and complex type glycans by the sequential action of GA resident glycosyltransferases. Typically, N-glycans develop into structures with at least two branches.

In contrast to N-glycans, O-glycans and protein-linked glycosaminoglycans (proteoglycans) are *de novo* synthesized, directly on the folded protein. This process is initiated in the GA, by the addition of D-GalNAc (mucin type O-glycans) or D-xylose (proteoglycans) to the side-chain hydroxyl group of serine or threonine. Subsequently, the glycans are turned into mature structures by the sequential action of a host of Golgi-resident enzymes. For mucin type O-glycans, this leads to a variety of core structures differing in their carbohydrate composition and linkage to the protein-proximal GalNAc residue,

which are further extended and capped with similar structures as for N-glycans. (Figure 1)

The glycans produced in the GA obviously depend on the repertoire of glycosylation enzymes present and their kinetic rate constants. Examination of transcripts encoding specific enzymatic machinery for glycan biosynthesis showed that many, but not all, changes in glycan abundance result from alterations in transcript expression of corresponding biosynthetic enzymes.^{8,9} This suggests that transcriptional regulation contributes significantly to the regulation of glycan expression.

Besides, systems glycobiology approaches have shown that additional factors and parameters of regulation should be considered, including processes regulating the localization of enzymes in the Golgi, the availability of substrates, enzyme kinetics^{10,11} The role of the GA in the translation of genome to glycome has been extensively reviewed in ref.⁶ and will not further be discussed in this review. We can generally state that the relative abundance of glycans in the total glycan composition of

a cell or tissue is in part dependent on the competition between glycosyltransferases with different activated donor substrate specificities for a certain glycoprotein acceptor. Furthermore, the concentration of sugar nucleotide donors, the association with specific chaperones, the modification or removal of sugars by additional enzymes and the trafficking dynamics of the acceptor glycoprotein throughout the secretory pathway are important factors contributing to the broad variety of glycans present on a cell.^{6,12}

When focusing on immunity, glycans are indispensable in virtually all signaling and cell-cell interactions. Glycan signatures present on healthy, inflamed or malignant tissue, or pathogens, provide signals for “self” or “non-self” recognition and are increasingly appreciated as key molecules in regulating immunity versus tolerance.

For example, during the initiation of innate immune responses, the microbial molecular patterns that are recognized often are glycoconjugates. In adaptive immunity,




Figure 1. Overview of human N- and O-glycosylation in the Golgi apparatus. On the left side, the synthesis of a human glycoprotein with several relevant complex-type N-glycans is shown. In the *cis* Golgi, mannosidase I (ManI) activity leads to a $\text{Man}_5\text{GlcNAc}_2$ that can be further modified in the medial Golgi. N-acetylglucosaminyltransferase I (GnTI) activity commits the glycan to the complex or hybrid type. Mannosidase II (ManII) activity, followed by several N-acetylglucosaminyltransferases then further commits the glycan to the complex type. If only N-acetylglucosaminyltransferase II (GnTII) acts on it, the result is a biantennary complex type N-glycan. GnTIV and/or GnTV activity then generates different triantennary or a tetraantennary complex type glycan. Fucosyltransferase VIII (FucTVIII) can act on any complex or hybrid type glycan to add a core α -1,6-fucose in the medial Golgi. Afterward, in the trans Golgi, galactosyltransferases (GalT), fucosyltransferases (FucT), sialyltransferases (SiaT) or a combination of GnTs and GalTs synthesize different capping moieties (sialylation, poly-LacNAc repeats, Lewis antigens) on N-glycans.

The right side of the figure shows mucin-type O-glycosylation biosynthesis. Polypeptide-GalNAc-transferases (ppGalNAcTs) initiate O-glycosylation in the *cis* Golgi, which is followed by the action of one or two core synthesizing enzymes: core 1 galactosyltransferase (C1GalT), core 2 N-acetylglucosaminidase I, II or III (C2GnTI/II/III) and core 3 N-acetylglucosaminidase (C3GnT), resulting in the synthesis of four so-called core structures. Core 1 and 2 are common, while core 3 and 4 have a restricted expression pattern. Two SiaT activities in particular (ST6GalNAc and ST3Gal) can add N-Acetylneuraminic acid to the Tn antigen or core 1 (T antigen) to generate the sialyl-Tn or sialyl-T antigen (STn or ST antigen). Several GalTs, GnTs, FucTs and SiaTs can act on the core structures to introduce further branching and terminating structures (not shown). Note that four more core structures (core 5–8) are known, but since their occurrence is extremely rare, they are not shown here. This figure has been adapted from De Wachter *et al.* with permission.⁷

glycans are involved in the alignment of the immunological synapse, in the generation and loading of antigenic peptides into MHC class I and in MHC class II antigen processing. These effects of glycans on immunity are reviewed by Baum et al.¹³ In this review, we will focus on the role of glycans in human T cell homeostasis and their function in T cell immunotherapy for cancer (Figure 2).

Glycan-binding proteins

In most cases, no single function can be attributed to a specific type of glycan. The function of a glycan is highly specific to the glycoprotein to which it is linked and the density at which it is present on a protein or on a biological surface, and it often relies upon the binding to glycan-binding proteins (GBPs). GBPs are characterized by one or more carbohydrate recognition domains and are often oligomeric or membrane bound. As the interactions between monosaccharides and proteins are often intrinsically weak, GBPs engage in multivalent interactions in order to confer avidity and specificity to their binding interactions with larger glycan structures or glycan-carrying surfaces, while their interactions are still tunable by alterations in the density of the glyco-epitopes to which they bind. GBPs are present in all organisms, ranging from microbes to humans and are involved in diverse biological processes, including immune responses. It will become clear from the following paragraphs that a particular glycan can be bound by several GBPs, and thus exerting pleiotropic effects. Since we will focus on the role of glycans and GBPs in human T cell function, we will first briefly introduce three types of GBPs with important roles in T cell responses.

Galectins

Galectins are a type of soluble, mammalian glycan-binding proteins grouped because of their common carbohydrate recognition domain (CRD) structure. It is because of variations in the amino acid sequence of this CRD that distinct Galectins have different glycan ligand specificities. As such, 16 different Galectins can be discerned.¹⁴ N-acetyllactosamine is the ligand recognized by Galectins on the glycan moiety on both glycolipids and glycoproteins. The affinity of these interactions is proportional to the N-acetyllactosamine content of the glycoprotein or -lipid and the fine glycan structure. The spatial organization and modifications by glycosyltransferases are also contributing to the specificity of the interaction. For example, incorporation of fucose slightly improves Galectin-1 and Galectin-3 binding.¹⁵

Galectins exert a broad range of effects during all aspects of T cell mediated immunity by the formation of lattices on the T cell surface.¹⁶ In this way, they serve both to amplify or resolve immune responses. The precise effect varies depending on the tissue context, the intracellular or extracellular localization of the Galectin, the (patho)physiological condition and the presence of other regulatory mechanisms. Galectin-1, -3 and -9 are the main Galectins affecting T cell function, as will be discussed further below.

Selectins

Selectins are a subtype of C-type Lectin receptors (CLRs), membrane anchored GBPs which bind to sialylated, fucosylated or sulfated glycans, mainly on the O-glycan chains of glycoproteins or proteoglycans and on glycolipids. Selectins can be further subdivided into E-, P- and L-Selectin based on their expression profile and the glycan ligands to which they bind. While during inflammation, L-Selectin expression is induced in leukocytes, the expression of E-Selectin is induced on the vascular endothelium, and P-Selectin expression or translocation is induced on both vascular endothelium and platelets respectively. E- and P-Selectin bind sLe^x antigen (sialylated, fucosylated lactosamine core structures – sLe^x). The major glycoprotein ligand for P-Selectin, termed P-Selectin glycoprotein ligand-1 (PSGL-1), has sulfated tyrosine residues adjacent to a core-2-based O-glycan expressing SLe^x.¹⁷ Ligands for L-Selectin contain 6-sulfo-sLe^x moieties on mucin-type O-glycans and N-glycans. Synthesis of the Selectin ligands mainly depends on the expression of the relevant fucosyl- and sialyltransferases. In the absence of these enzymes, lymphocyte homing to peripheral lymph nodes or sites of inflammation is strongly attenuated.^{18,19}

Siglecs

Siglecs (sialic acid-binding immunoglobulin-type lectins) are a family of immune regulatory receptors predominantly found on the cells of the hematopoietic system. They have different binding preferences for sialylated glycan ligands. Siglecs are categorized into two subgroups that are functionally diverse, even in terms of signaling mechanisms. One group includes the structurally conserved Siglecs consisting of Siglec-1 (Sialoadhesin), Siglec-2 (CD22), Siglec-4 (myelin-associated glycoprotein, MAG) and Siglec-15. Another subgroup includes Siglec 3/CD33 and CD33-related Siglecs which have high homology to CD33 in their extracellular domains, contain at least one classic immunoreceptor tyrosine-based inhibition motif (ITIM) and show high variability in number between species and even vary between individuals of the same species, e.g. in humans. There is no evidence for a significant degree of functional redundancy either in the Siglecs conserved across species or in the CD33-related group of Siglecs. Most Siglecs function as inhibitory receptors on innate and adaptive immune cells. Binding to and subsequent signaling by both cis-ligands (expressed on the same cells; considered markers of 'self') as well as to sialoglycoconjugates presented in trans (e.g. on a neighboring cell or pathogen) attenuates immune responses.²⁰

Glycosylation in human T cell homeostasis

Role of glycosylation in T cell development

Glycans regulate key physiological steps within T cell biology such as T cell development and thymocyte selection, T cell activity and signaling as well as T cell differentiation and proliferation (Table 1).

T cell **migration** is thought to be largely dictated by O-glycan modifications on Selectin ligands.²⁹ Before they can populate peripheral tissues, hematopoietically derived

Table 1. Role of T cell glycosylation during T cell development, activation and signaling.

	Glycosylation	Effect
T-CELL DEVELOPMENT	α -(1,3) fucosylation of PSGL-1	● Homing of T cell precursors to the thymus (<i>P</i> -Selectin binding) ^{18,19}
	O-GlcNAcylation by <i>OGT</i>	● β -selection, maturation of single positive CD4 ⁺ and CD8 ⁺ T cells ^{21,22}
	α -(2,3) and α -(2,6) sialylation of cell surface glycoproteins	● Maturation of single positive CD4 ⁺ and CD8 ⁺ T cells ²³⁻²⁵ ● Regulation of TCR affinity-dependent negative selection ^{16,26-28}
	Core 2 O-glycosylation	● Extravasation across activated vascular endothelium and entry in non-lymphoid tissue ^{29,30}
T CELL ACTIVATION AND SIGNALING	N-glycan branching by <i>MGAT5</i>	● Increased N-acetylglucosamine modifications (ligand of Galectins) ● Binding by Galectins holds CD45 and TCR signaling complex in close proximity to prevent low-avidity T cell activation ^{31,32} ● Promotion of Th2 development over Th1 responses ³³ ● N-glycan branching on CTLA-4 enhances its retention at the T cell surface, suppressing T cell activation and promoting immune tolerance ³⁴⁻³⁶
	N-Glycosylation of MHC I	● Important for protein folding, trafficking and peptide loading ³⁷⁻⁴⁰
	N-Glycosylation of MHC II	● Modulation of glycopeptide binding and presentation ⁴¹⁻⁴⁴
	α -(2,6) sialylation of CD45	● Capping of the terminal Gal- β -1,4-GlcNAc-binding sites, used as a ligand by Galectin-1, with consequent reduced Galectin-1 induced cell death ● Inhibition of CD45 clustering, leading to diminished signaling ⁴⁵
	N-Glycan branching of CD25	● Increased surface expression and retention, thereby controlling T cell differentiation ⁴⁶
	O-GlcNAcylation of transcription factors involved in IL2-signaling	● Regulation of IL-2 production upon TCR stimulation ²¹
	Sialylation of CCR7 receptor	● Modulation of T cell homing to the lymph nodes. Sialylation provides steric hindrance for ligand binding, diminishing receptor potency and decreasing signaling ability; reflected by low CCR7 sialylation on recirculating T cells and high CCR7 sialylation on activated T cells ⁴⁷

T cell precursors exit the bone marrow and must home to the thymus to mature from the double negative (DN) state toward double positive (DP) and undergo positive and negative selection to mature into either a CD4⁺ or CD8⁺ T cell. This homing is dependent on *P*-Selectin expression on thymic endothelial cells and the ability of T cell precursors to generate *P*-Selectin ligands.⁴⁸ Trafficking of T cell precursors to the thymus is impaired in the absence of PSGL-1 glycan fucosylation (α -1,3) since the latter is required for binding to *P*-Selectin on thymic epithelium.⁴⁹

The early thymic progenitor cells are CD4 and CD8 DN, and are also T cell receptor (TCR) negative. DN1 cells can give rise to T cells, NK cells, B cells, and macrophages. TCR rearrangement begins in DN2 cells. Commitment to the T cell lineage occurs during the transition from the DN2 to the DN3 stage. DN3 cells that have successfully rearranged their TCR β -chain, form a pre-TCR complex with a pre-TCR α chain. This pre-TCR enforces β -selection and supports proliferation and differentiation bringing cells from DN3 to DN4. DN4 cells upregulate CD8 and CD4 to become DP and initiate rearrangement of the TCR α locus. After successful rearrangement, a TCR $\alpha\beta$ complex is expressed on DPs that undergo positive or negative selection and become MHC class I or II restricted. This process upregulates glucose and glutamine uptake with a concomitant increase in O-GlcNAc levels.²¹

O-GlcNAcylation has been shown to be required throughout **T cell development**.⁵⁰

Mice that are conditionally knockout for *Ogt* in DN thymocytes, contain substantially less thymocytes and mature CD4⁺ and CD8⁺ T cells, a phenotype consistent with a loss of β -selection.²¹ Deletion of *Ogt* just before the DP stage, causes failure to differentiate to mature single positive (SP) CD4⁺ or CD8⁺ T cells, although numbers of DP cells are not influenced.²¹ Increased expression of *OGT* in T cells from women with active lupus highlights the importance of O-GlcNAc regulation for normal immune homeostasis.²²

During **T cell maturation** from DP thymocytes into SP T cells, both α -(2,3)- and α -(2,6)-sialylation of cell surface glycoproteins is increased, as is experimentally shown by increased *Sambucus nigra* lectin (SNA) binding (specific for α -(2,6)-sialylation) and decreased peanut agglutinin (PNA) binding (specific for non-sialylated core-1 O-glycans).^{23,24} These findings are confirmed in β -Galactoside- α -2,6-Sialyltransferase 1 (ST6 GalI)-deficient mice, where DN populations are reduced, whereas a reduction in mature CD8⁺ SP thymocytes is demonstrated in ST3 GalI-deficient mice (reduced sialylation of core 1 O-linked glycans).²⁵

Following their development and **exit from the thymus**, naive T cells enter the periphery where they continually survey the spleen and secondary lymphoid organs for an encounter with cognate antigen. Increased sialic-acid modifications

of glycans on differentiated SP CD8⁺ thymic T cells decrease the binding avidity of CD8 for MHC I molecules, thereby regulating TCR affinity-dependent negative selection.^{16,26–28}

Naive T cells express high levels of L-Selectin (CD62L) and are defined as being CD44^{lo}/CD62L^{hi} in mice and CD45RA⁺/CD62L^{hi} in humans. Once a naive T cell is activated by antigen binding and co-stimulation, CD62L expression ceases and T cells become effector cells, most of them having a limited life span. Those that survive become long-lived memory T cells, which are characterized by 2 subsets, being central memory (T_{CM}, CD62L⁺ CCR7⁺) or effector memory (T_{EM}, CD62L⁻ CCR7⁻) T cells. T_{CM} actively survey lymph nodes due to the presence of L-Selectin, whereas T_{EM} are limited to the circulation, spleen and non-lymphoid tissues due to its absence.

Naive T cells cannot synthesize core 2 O-glycans or bind to P (CD62P)- and E-Selectin (CD62E), which essentially excludes them from entering non-lymphoid tissues. Following stimulation of the T cell receptor, both CD8⁺ and CD4⁺ T cells increase expression of core 2 β -1,6-N-acetylglucosaminyltransferase-I (GCNT1), α -1,3-fucosyltransferase-VII (FUT7), and likely additional enzymes that facilitate core 2 O-glycan synthesis. This post-translational modification transforms surface proteins such as PSGL-1 and CD43 into P- and E-Selectin ligands to direct extravasation across activated vascular endothelium and entry into non-lymphoid tissues. Effector CD8⁺ T cells have increased binding to PNA, indicating lowered capping of core 1 O-glycans with α -2,3-linked sialic acids.^{29,30}

Role of glycosylation in T cell activation

Glycosylation is also involved in the regulation of T cell activation and functioning, mainly by N-glycosylation of the TCR and co-receptors (Table 1). Glycans can act to stabilize complexes at the immunological synapses, serving as a protective coat for the underlying protein by inhibiting degradation by proteases. They can suppress aggregation of TCRs on the membrane, thereby reducing auto-activation.⁵¹

Initiation of T cell responses depends on the recognition of an antigenic epitope presented in the context of a class I or class II MHC (MHCI/II) molecule. Glycans on both the TCR $\alpha\beta$ chains and MHCII can impact T cell activation. N-glycans present on the TCR are thought to play a role in cell surface localization and the orientation and organization of the molecule itself rather than directly influencing MHC interactions.

β -1,6-N-acetylglucosaminyltransferase-V (MGAT5) is the enzyme responsible for the initiation of GlcNAc- β -(1,6)-branching on N-glycans and is involved in multiple aspects of T cell activation. β -(1,6)-N-glycan branching leads to an increase in N-acetylglucosamine modifications, the ligand of Galectins. It has been demonstrated that absence of *Mgat5* and thus a decrease in N-acetylglucosamine, lowers T cell activation thresholds *in vitro* by enhancing TCR clustering due to the absence of Galectin-glycoprotein lattice formation.³¹ This Galectin-mediated lattice is responsible for holding CD45 and the TCR signaling complex in close proximity via their O- and N-linked glycans (respectively) to

prevent low-avidity T cell activation.³² Along the same line, an increased incidence of autoimmune disease is seen in the absence of *Mgat5 in vivo*.⁵² Furthermore, negative regulation of TCR signaling by β -1,6-GlcNAc-containing N-glycans promotes development of Th2 over Th1 responses, enhances Th2 polarization, and suggests a mechanism for the increased autoimmune disease susceptibility observed in *Mgat5*^{-/-} mice.³³ On the other hand, *Mgat5* expression can be induced by the anti-inflammatory cytokine IL-10, decreasing antigen sensitivity of CD8⁺ T cells during chronic infection.⁵³

N-glycans on MHCI are important for protein folding and trafficking to the cell surface and peptide loading of MHCI molecules.^{37–40} MHCI molecules are heterodimers comprised of a polymorphic transmembrane heavy chain and non-glycosylated β 2-microglobulin. Within the heavy chain, the single conserved site for N-glycosylation across all known alleles is Asn86. The relative homogeneity of the complex type N-glycans on human MHCI suggests that the glycan might play a role in differentiating self and non-self,⁵⁴ however, this possibility remains unexplored.

MHCII has three highly conserved N-glycosylation sites, two on the α -chain (Asn78 and Asn118) and one on the β -chain (Asn19). Glycosylation of MHCII is not required for proper folding or trafficking of MHCII and shows a great variety between different cell types (e.g.: DC vs. B cell vs. macrophage), such as differences in degree of terminal sialylation and branching patterns which can directly modulate glycopeptide binding and presentation,^{41–44} while this has no impact on binding of unmodified peptide antigens. It is speculated that the glycans serve to extend the binding platform of MHCII to accommodate the larger glycoantigen molecules.

Glycosylation of transmembrane T cell surface proteins

CD43 and CD45 are the two most abundant glycoproteins present on the T cell surface and are expressed throughout all stages of T cell development, from DN thymocytes to memory T cells. CD43 and CD45 are decorated with O- and N-glycans, and these molecules function in T cell activation, differentiation and migration, T cell receptor signaling and T cell apoptosis.⁵⁵ Alternatively spliced isoforms of CD45 display different glycosylation sites. The expression of ST6GalI transferase has been proposed to modulate binding of Galectin-1 to CD45 on T cells;⁴⁵ α -2,6-sialylation of CD45 glycans caps the terminal Gal- β -1,4-GlcNAc-binding sites used as a ligand by Galectin-1, implying that reduced ST6GalI expression in activated T cells could lead to increased binding of Galectin-1, resulting in cell death. Furthermore, α -2,6-sialylation was shown to inhibit clustering of CD45 on T cells, leading to diminished signaling (Table 1).⁴⁵

CD25 is the high-affinity α subunit of the IL-2 receptor and surface expression and retention is modulated by N-glycan branching, thereby controlling T cell differentiation with impact on immune tolerance.⁴⁶ Abolishing complex and hybrid type N-glycosylation in favor of the oligomannose type on CD25 via *Mgat1* deletion reduced surface expression and retention while upregulation of branching via GlcNAc

supplementation or *Mgat5* overexpression had the opposite effect, by raising CD25 surface levels. Increased β -1,5-N-glycan branching on CD25 also skews IL-2 signaling toward iTreg differentiation over Th17 differentiation.⁴⁶ Furthermore, transcription factors both upstream (e.g. NFAT and NF κ b),^{56,57} and downstream (cMyc) of IL-2 signaling require O-GlcNAc modifications for proper function.²¹ For example, chemical inhibition of OGT in primary human T cells decreases production of IL-2 upon TCR stimulation. Lymph node homing of T cells and antigen-experienced DCs relies on the chemokine receptor CCR7 and its two ligands, CCL19 and CCL21. Leukocyte subsets express distinct patterns of sialylation of the human CCR7.⁴⁷ This sialylation provides steric hindrance for ligand binding, rendering the receptor less efficient at low chemokine concentrations. DCs secrete glycosidase that deglycosylates CCR7 on T cells, thereby enhancing receptor potency and increasing its signaling ability, while inhibiting receptor endocytosis.⁴⁷ Consistent with this finding is the observation that naive, recirculating T cells only express limited amounts of sialylated CCR7, whereas high levels are seen on activated T cells. Glycosylation of the receptor acts as a swinging door, providing on the one hand steric hindrance for chemokine binding and on the other hand, retaining bound chemokines within the binding pocket, keeping the receptor susceptible for desensitization.

Importance of glycosylation in the interaction of human T cells with tumor cells

One of the hallmarks of cancer biology is the altered tumor cell glycosylation characterized by enhanced branching and sialylation and incomplete glycan synthesis. Virtually all cancer types are associated with expression of common glycan epitopes such as Sia-Le^x and Sia-Le^a. Expression of these Siglec/Selectin ligands is correlated with enhanced metastasis and poor prognosis of cancer patients suffering from colon, gastric, prostate, renal, pancreatic or lung cancer.^{58–60} Moreover, neo-antigens originate through glycosylation of tumor proteins, serving as targets for tumor-specific T cells.^{61,62} In this paragraph, we will highlight the importance of glycosylation in the interaction of human T cells with tumor cells, often contributing to the creation of T cell killing resistance pathways in cancer.

Immune checkpoints

It is well established that tumors are inherently immunosuppressive, both due to the expression of immune checkpoint molecules (e.g. programmed death ligand-1, PD-L1) and expression of immune-inhibitory molecules (e.g. anti-inflammatory cytokines and chemokines). Unlike CTLA-4 or programmed cell death protein-1 (PD-1), which are primarily expressed on immune cells, PD-L1 is expressed in cancer cells and macrophages and plays a major role in inhibiting the immune response. Binding of PD-L1 to its receptor, PD-1 on T cells, inhibits T cell proliferation, cytokine production and cytolytic activity. The majority of PD-L1 on human tumor tissues and cancer cell lines is glycosylated, which

stabilizes the PD-L1 protein, thus strengthening inhibition of the immune response.^{63,64}

Growth arrest of activated T cells is dependent on induction of the immune checkpoint cell surface cytotoxic T-lymphocyte-associated-antigen-4 (CTLA-4). CTLA-4 competes with the sequence-related receptor CD28 for CD80/86 ligand on antigen-presenting cells to positively (in the case of CD28) or negatively (in the case of CTLA-4) regulate T cell proliferation.⁶⁵ TCR activation signaling normally leads to increased *Mgat5* activity and N-glycan branching. It was demonstrated that in *Mgat5*^{-/-} T cells, the fractions of T cells expressing CTLA-4 on their cell surfaces, as well as the CTLA-4 expression levels are decreased following low levels of TCR stimulation while CD28 surface levels are comparable in *Mgat5*^{-/-} vs WT T cells.³⁴ On the contrary, increased N-glycan branching on CTLA-4 molecules upon TCR activation is shown to enhance its retention at the T cell surface, thereby suppressing T cell activation and promoting immune tolerance (Table 1).^{35,36}

Tim-3 is an immune checkpoint receptor that shares a similar expression pattern as PD-1 on T cells. Tim-3 is a coinhibitory receptor, meaning that ligand binding leads to inhibition of T cell proliferation and cytokine production. T cell mediated immunity is further regulated through the interaction of Tim-3 with Galectin-9 (see further).⁶⁶

Galectins

Galectin-9 is one of the ligands of Tim-3 and negatively regulates T cell immunity.⁶⁷ A recent study shows that the interaction between Tim-3, expressed on T cells and Galectin-9, expressed in the tumor environment, is implicated in the resistance to PD-1 blockade in cancer patients (Table 2).⁷⁸ Furthermore, increased serum levels of Galectin-9 and Tim-3 were observed in the plasma of patients with acute myeloid leukemia and chronic lymphocytic leukemia, turning Galectin-9 into a potential target in leukemia.^{79–81}

Galectin-1 functioning is involved in many signaling pathways leading to anti-inflammatory activities by targeting multiple types of immune cells.⁶⁸ In T cells, it is controlling T cell effector function homeostasis by regulating activation, differentiation, survival and cytokine production.⁶⁹ Galectin-1 is known to be a pro-tumorigenic and proangiogenic factor in cancer progression and has been associated with immune disorders such as HIV.⁸² Overexpression of Galectin-1 was observed to be linked to progression of many types of cancers, including osteosarcoma, breast, lung and prostate cancers and in melanoma. The secretion of Galectin-1 by tumors leads to tolerogenic signaling and immune suppression. Therefore, Galectin-1 is an emerging biomarker for the diagnosis, prognosis and treatment plan of several cancers and interest is arising in targeting Galectin-1-glycan interactions in the attempt to overcome cancer mediated immunosuppression (Table 2).⁸³

Galectin-3 has the unique feature of being able to crosslink its binding partners through the presence of an oligomerization domain. Binding of Galectin-3 to glycoproteins has both pro- and anti-apoptotic effects on T cells, dependent on its localization. Intracellular Galectin-3 blocks apoptosis by

Table 2. Role of glycan binding proteins in T cell cancer immunity.

	GBP	EFFECT	PRO OR ANTI-TUMORIGENIC
GALECTINS	Galectin-1	● Induction of tolerogenic signaling and immune suppression ^{68,69}	PRO
	Galectin-3 Intracellular (T-cell) Extracellular	● Blocking T cell apoptosis ⁷⁰ ● Negative regulation of T cell activation by destabilizing the immunological synapse and by promoting downregulation of the TCR. ● Binding to CTLA-4 and Lag3 leads to inhibition and cell death of activated T cells ^{71,72}	ANTI PRO
	Galectin-9	● Negatively regulates T cell immunity by binding to Tim-3 ⁶⁷	PRO
SELECTINS	L-Selectin On T cells On leukemia cells	● Acquisition of T cell effector functions ⁷³ ● Improved trafficking and distribution abilities (dissemination) (CLL patients) ⁷⁴	ANTI PRO
	SIGLECS	Siglec-9 On TILs	● Effector memory T cells with higher functional responses after stimulation ^{75,76}
Siglec-15 On tumor cells and TIMs		● Suppression of antigen-specific T cell responses ⁷⁷	PRO

stabilizing the mitochondrial membrane and preventing cytochrome c release,⁷⁰ while extracellular Galectin-3 binds to glycoproteins such as CTLA-4 and Lag3 on the T cell surface, leading to inhibition and cell death of activated T cells.^{71,72} Endogenous Galectin-3 produced by activated T cells is recruited to the immunological synapse. There it negatively regulates T cell activation by destabilizing the immunological synapse through direct interactions with glycoproteins associated with the T cell receptor, and by promoting downregulation of the TCR.^{84,85} Another interesting finding is that binding of Galectin-3 to antigen-specific activated CD8 β T cells inhibits their effector function within the tumor micro-environment (Table 2).⁷¹

Selectins

Selectins play important roles during different stages of cancer progression, including recruitment of leukocytes to the tumor site, immune evasion mechanisms, dissemination and extravasation. As L-Selectin is believed to be involved in the acquisition of T cell effector function, it confers protective antitumor immunity. Consistent with this, accumulation of myeloid derived suppressor cells (MDSCs) was observed in cancer patients and is known to suppress both the innate and adaptive antitumor response through processes comprising downregulation of L-Selectin.⁷³ In contrast, L-Selectin present on the surface of leukemia cells promotes cancer progression in CLL patients by affecting their trafficking and distribution abilities (Table 2).⁷⁴

Siglecs

Siglec-15 is broadly upregulated on human cancer cells and tumor-infiltrating myeloid cells, directly suppressing antigen-specific T cell responses *in vitro* and *in vivo*.⁷⁷ Tumor-infiltrating CD11b⁺ cells from Siglec-15 KO mice significantly promoted CD8⁺ T cell proliferation as well as cytokine secretion compared to those from wild type mice (Table 2).⁷⁷

Siglecs are expressed at very low levels on normal T cells. Several recent reports demonstrate the expression of Siglec-9 on tumor-infiltrating cytotoxic CD8⁺ T cells in multiple types of cancers (colorectal, ovarian and non-small cell lung cancer (NSCLC), and melanoma).^{75,76} These Siglec-9-expressing tumor-infiltrating lymphocytes (TILs) as well as Siglec-9⁺ CD8⁺ T cells, in lower numbers in the peripheral blood of melanoma patients and healthy donors, exhibited an effector memory phenotype. Co-expression with several known inhibitory T-cell receptors, e.g. PD-1, CTLA-4 and TIM-3, is seen. Despite this inhibitory phenotype, functional responses of Siglec-9⁺ CD8⁺ T cells to CD3/C28 costimulation are higher than those observed for their Siglec-9⁻ counterparts *in vitro* (Table 2).⁷⁶

A note of caution

While all of the studies done have provided valuable insight on the potential modulatory function of altered glycosylation in T cell biology, it should be noted that many conclusions have been drawn from rather simplified *in vitro* cellular immunology assay systems. To what extent these insights and alterations of glycans and their interactions with glycan binding proteins have an impact in realistic *in vivo* models of disease and in patients often remains to be established. The manipulations of the surface glycome of T cells and/or tumor cells affect the entire glycome in most cases, not restricted to one particular glycosylated molecule. Hence, the overall effect of such glycome engineering should still be considered highly unpredictable and worthy of exciting further research.

Targeting the tumor or T cell glycome for therapeutic purposes

Cancer immunotherapies targeting the interaction of human T cells with tumor cells by use of agents that bind to glycans or glycan binding proteins

Many studies have aimed to induce specific immune responses against tumor-associated glycans and glycoproteins.⁸⁶ For

example, a high anti-glycan antibody response could be driven by a combination of adjuvants and an optimization of T cell help through the use of repetitive immunizations with a glycopeptide-displaying particle resulting in the elicitation of anti-glycopeptide-specific T cells.⁸⁶ In another glycan-enhanced tumor vaccination approach, the coupling of glycans such as Lewis antigens to tumor antigens could facilitate internalization of the antigen by DCs due to improved recognition by DC-SIGN. This in turn favors antigen cross presentation and stimulation of tumor-specific T cell responses.⁸⁷ Recently, a carbohydrate-based vaccine was developed for metastatic breast cancer targeting the glycolipid Globo-H. The vaccine induced antibodies to target not only Globo-H but also SSEA3 and SSEA4. Together, these three targeted glycolipids were found to be uniquely expressed not only on the cell surface of breast cancer but on 15 additional cancer types, broadening the application of this vaccine, which is currently tested in a phase I clinical trial (NCT02310464).^{88,89}

In a different approach, cell-based immunotherapy utilizes living cells to harness the body's natural immune system to fight disease. Chimeric antigen receptors (CARs) have been developed that recognize cancer-associated glycan epitopes of glycolipids and glycoproteins, such as the Lewis y antigen (Le^y), the sialyl Tn O-glycan epitope (TAG72), disialoganglioside GD2 and a Tn glycoform of MUC-1.⁹⁰

Interfering with the interaction of surface glycans and their lectin receptors, for example by adding antibodies that block tumor-associated glycan-lectin interactions is yet another strategy which is explored as antitumor therapy and several applications look very promising and/or are already used in the clinic.^{64,91–94}

Considering the abundance of Siglec ligands on the surface of tumor cells and the inhibitory nature of many Siglecs, multiple studies have recently been initiated, investigating the effect of altering the levels of sialylation on tumor cells.⁹⁵ They are targeted using blocking antibodies, aiming to improve cancer immunotherapy.⁹⁶ Anti-Siglec-15 monoclonal antibody (targeting tumor-infiltrated macrophages-TIMs) inhibited the growth of established tumors in murine models.⁷⁷ A clinical trial is ongoing to test the effect of an anti-human Siglec-15 mAB (NC318) in solid tumors, with promising very early results recently reported.⁹⁷ Worth noting is that Siglec-15 KO mice do not develop obvious physical abnormalities, which is consistent with rare expression on normal tissues and suggests minimal adverse effects for Siglec-15 blockade therapy. Recently, also Siglec-9 was considered as interesting target for cancer immunotherapy.^{75,76} Targeting immunologic checkpoints that include dominant regulatory circuits confined to the tumor microenvironment, such as Siglec-9/-15 receptor-ligand interactions, allow to selectively unleash the restricted repertoire of TILs and TIMs, while reducing the potential for uncontrolled T cell activation and associated immune-related adverse events.⁹⁸

Interfering with Selectin and Galectin functioning can also influence the interaction of T cells with tumor cells.^{95,99} For example, interference with L-Selectin-mediated trafficking by treating patients with idelalisib, a phosphoinositide-3-kinase δ inhibitor, in high endothelial venules could limit dissemination of CLL to lymph nodes.⁷⁴ Galectin inhibitors have

been evaluated in combination with chemotherapy drugs (5-fluorouracil) against solid tumors in several clinical trials, however, only one trial has been completed so far, suggesting that not all Galectin inhibitors are effective.¹⁰⁰ Given the pleiotropic effect of galectins, there may be a narrow safe dosage window, although data in humans remains scarce. Immunotherapy using monoclonal antibodies blocking immune checkpoint molecules has been combined with Galectin inhibitors to enhance the therapeutic effect in one study.¹⁰⁰ TIM-3 inhibitors have shown similar efficacy as that of PD-1 inhibitors in preclinical research and many clinical trials are now focusing on the use of anti-TIM3 blocking antibodies.¹⁰¹

Glycan-engineering and implications in immune therapy

To date, the precise experimental adaptation of glycan structures on a specific protein in a living cell is most often not possible, except for the removal or addition of glycosylation sites. Therefore, instead of focusing on specific glycoproteins, a systems approach is taken in which the structure of glycans on the cell surface as a whole is perturbed. This allows to link changes in overall cellular glycosylation with cellular fates and functions, but often makes it more difficult to dissect the precise molecular mechanisms underlying glycosylation-mediated signaling events and the downstream cellular consequences. Alteration of cellular glycosylation capacity has an impact on multiple cell surface receptors, their biogenesis, biophysical behavior and signal transduction. What is measured is the integrated result of all of these alterations on cellular behavior. But of course, it is cellular behavior that matters in the end for therapeutic effects. The ability to remodel glycans on the cell surface could hence lead to novel approaches to manipulate cellular physiology and functional behavior.

The potential of glycosylation engineering to enhance therapeutics has been investigated and utilized extensively in the field of protein biopharmaceuticals, for example in anti-cancer antibodies.^{102,103} Cell-based therapies are emerging fast in the treatment of diverse diseases, including autoimmune diseases and cancer. In order to enhance the function of therapeutic cells, extensive studies are being performed seeking for improved survival, proliferation and differentiation of these cells. In the following sections, we will describe glycode-sign strategies used to endow therapeutic cells with new favorable properties and functions.

Genetic engineering approaches

Genetic engineering via gene knockdown, knockout, over-expression, knock in or selective nucleotide mutations can be used to target glycosylation enzymes or complete pathways in order to reduce or silence undesirable glycosyltransferase activities or to enhance certain aspects of glycosylation.

These genetic engineering approaches are based on developments in the field of genome engineering.^{104–106} Although these techniques are very versatile and give us the opportunity

to make permanent cellular glycan modifications, it has to be kept in mind that potential off-target effects, inefficient delivery systems, confounding epigenetic regulation of glycosylation pathways, compensatory glycan alterations and unpredictable alterations in cellular physiology can have a detrimental impact on the intended results. Fast developments in the genome editing field result in continually improving and newly emerging tools, which should eliminate several of these problems in the coming years.¹⁰⁷

Some interesting results were already obtained using genetic glycoengineering. For example, selectively removing conserved N-glycosylation sites in the constant regions of TCR α and β -chains increased the functional avidity (reflected by increased cytokine secretion, lytic capacity and tumor cell recognition) of T cells transduced with modified TCRs. This is caused by an improved $\alpha\beta$ TCR multimerization and decreased TCR-MHC dissociation, ultimately increasing the recognition of tumor cells bearing the target antigen (Table 3).¹⁰⁸

In another study, overexpression of rat ST6GalI in murine and human T cell lines resulted in increased α -2,6-sialylation of N-glycans, thereby shielding LacNAc residues from Galectin-1 binding and reducing Galectin-1 induced cell death of the T cells (Table 3).⁴⁵

Using a genome-wide loss-of-function CRISPR-Cas9 based screening method, Okada *et al.* identified FUT8 (the core fucosyltransferase) as a positive regulator of cell-surface expression of PD-1, a marker of T cell exhaustion. Inhibition of FUT8 by genetic ablation reduced cell surface expression of PD-1 and enhanced T cell activation and anti-tumor immune responses (Table 3).¹⁰⁹

Metabolic glycoengineering

Metabolic glycoengineering (MGE) involves the incorporation of non-natural glycan constituents. This type of engineering is often exploited in order to label glycans for the purpose of imaging, tracking and identifying glycan structures.¹²⁰ On the other hand, the remodeling of glycan structures on the cell surface can provide a powerful means to modulate cellular functions and responses. In practice, living cells or even entire organisms are supplemented with synthetic monosaccharide precursors that either alter the natural flux through a biosynthetic pathway or substitute natural metabolites with non-natural analogs. These metabolites are processed by the natural biosynthetic pathway, eventually leading to altered glycoforms, potentially containing non-natural chemical groups. This approach is rather convenient because the analog can be directly added to the cell culture medium during therapeutic cell cultivation. However, the large-scale synthesis of the required monosaccharide analogs can turn out to be very expensive to implement such glyco-engineering strategies in real therapeutic cell manufacturing.

Inhibiting the biosynthesis of Galectin-1-binding N-acetyllactosamine (LacNAc) glycans via systemic delivery of non-natural fluorinated carbohydrate analogs increases the number of infiltrating tumor-specific cytotoxic T cells and intratumoral IFN- γ expression in mice.¹¹⁰ Alternatively, intratumoral injection of thiodigalactoside, a Galectin-binding variant of lactose with enhanced glycosidase stability, leads to an increase in tumor-infiltrating cytotoxic T cell numbers and reduced tumor growth (Table 3).¹¹¹ Furthermore, the use of

Table 3. Examples of glycan-engineering and its implications in immune therapy.

	Intervention	Effect
GENETIC ENGINEERING	Deletion of N-glycosylation sites in TCR chains	● Increased functional avidity by improved TCR multimerization and decreased TCR-MHC dissociation ¹⁰⁸
	Overexpression of ST6GalI (increased α -(2,6) sialylation)	● Shielding LacNAc residues from Galectin-1 binding, reducing Galectin-1 induced cell death of T cells ⁴⁵
	Genetic ablation of FUT8	● Reduced cell surface expression of PD-1 and enhanced T cell activation ¹⁰⁹
METABOLIC GLYCOENGINEERING	Inhibition of LacNAc synthesis	● Increased number of infiltrating tumor-specific CD8 ⁺ T cells and intra-tumoral IFN- γ expression ¹¹⁰
	Addition of Galectin-binding variant of lactose	● Increased TIL numbers and reduced tumor growth ¹¹¹
	Inhibition of fucosylation and sialylation	● Decreased Selectin ligand synthesis and impaired cancer cell adhesion and migration <i>in vitro</i> and prevention of metastasis <i>in vivo</i> ¹¹²
	Sialic acid biosynthesis blockade	● Enhanced T cell killing capacity ¹¹³
	Enhanced N-glycan branching	● Control of the T cell immune response ¹¹⁴
CHEMOENZYMATIC GLYCOENGINEERING	LacNAc labeling	● Biophysical probe for imaging or glycomics analysis ¹¹⁵
	LacNAc modification with antibodies to generate antibody-T cell conjugate	● Increased tumor targeting capacity and resistance to inhibitory signals ¹¹⁶
	Fucosyltransferase treatment of regulatory T cells	● Increased expression of sLe ^x antigens leading to improved trafficking, homing and engraftment ¹¹⁷
	PNGaseF treatment of regulatory T cells	● Increased proliferation of naïve and memory T cells ¹¹⁸
	Sialidase treatment of cytotoxic T cells	● Increased T cell activation and cytolytic activity ¹¹⁹

fluorinated fucose and sialic acid analogs blocks protein fucosylation and sialylation, leading to suppression of Lewis-x (Le^x) and sLe^x antigen biosynthesis.¹¹² This impairs cancer cell adhesion and migration *in vitro* and prevents metastasis formation *in vivo* in mice.¹²¹ Additionally, sialic acid biosynthesis blockade enhances tumor cell – T cell interactions and enhances the killing of tumor cells by cytotoxic T cells (Table 3).¹¹³ Further research is needed to unravel the mechanisms underlying the enhanced susceptibility of sialic acid-depleted tumor cells to killing by cytotoxic T cells. One hypothesis is that removal of negatively charged sialic acids could influence the biophysical interaction between tumor cells and T cells, for instance by affecting MHC I–TCR interactions and subsequent signaling events.^{26,122} In inflammatory bowel disease, metabolic supplementation of mucosal T cells with GlcNAc leads to enhancement of N-glycosylation branching on the TCR, thereby controlling the T cell immune response (Table 3).¹¹⁴

In an alternative metabolic glycoengineering approach, monosaccharide analogs are used to introduce non-natural chemical moieties (such as ketones, azides, alkynes, thiols, ...) in glycans, enabling bioorthogonal conjugation of small molecules such as toxins, drugs, imaging agents and polymers via click chemistry. Using this bioorthogonal click chemistry, a library of more than 60 different cell lines was generated with different sialic acid modifications, leading to dramatic increases in binding with Siglec family members. This enabled the study and steering of the complex interactions between sialic acid and their Siglec binding partners.¹²³ Whether any of this will be of relevance for safe enhanced cellular immunotherapy awaits further experimentation. Glycometabolic bioorthogonal chemistry can be utilized to establish a highly efficient viral transduction system for human primary T lymphocytes, thereby showing a great potential for clinical-engineered T-lymphocyte manufacturing.¹²⁴

In order to conclude this section, it is important to point out the complex and often-unpredictable interplay between metabolism, genetics and cell fate occurring during metabolic glycan engineering. Only further rigorous experimentation in therapy-relevant cell manufacturing conditions and suitable animal models of cancer (in particular using patient-derived human tumor cells) may reveal the concepts that are promising for translation into therapy.

Chemoenzymatic glycoengineering

Chemoenzymatic glycan labeling and modification is an emerging valuable tool to modify the glycan structures within a cell, and is complementary to metabolic glycan engineering. Instead of using the cell's own glycan biosynthetic machinery to incorporate unnatural monosaccharides, chemoenzymatic glycoengineering utilizes a recombinant glycosyltransferase to transfer natural or unnatural monosaccharides equipped with a bioorthogonal chemical tag to glycoconjugates, thereby endowing them with novel structural characteristics and function.¹²⁵

As described in the previous section, imaging glycans *in vivo* is possible using bioorthogonal chemical reporter strategies in which cells or even complete organisms are supplemented with azide- or alkyne-tagged monosaccharide

precursors. A limitation of this strategy is that each monosaccharide is normally incorporated into a multitude of different glycans, making it impossible to label higher order glycans uniquely by feeding the biosynthetic pathway with unnatural monosaccharides. Chemoenzymatic approaches were reported for the labeling of complete cell surface glycans containing LacNAc. In this approach, recombinant microbial α -(1,3)-fucosyltransferase treatment was used to label the LacNAc moieties with clickable fucose analogs, which can be used as biophysical probes for imaging or glycomics analysis. By probing LacNAc levels in this way, it was possible to differentiate lymphocytes exhibiting different activation states (Table 3).¹¹⁵

Ex vivo enzymatic treatment of immune cells has led to promising results in the field of anti-graft versus host disease adoptive cell therapy. When regulatory T cells were treated with recombinantly produced Fucosyltransferase-VI (FUT6) and the GDP-Fucose donor substrate, an increase in sLe^x antigens was observed on their cell surface, leading to an improvement in trafficking, homing to the site of inflammation and engraftment of these regulatory T cells (Table 3).¹¹⁷ Similarly, increased homing of CAR-T cells to the bone marrow was observed following the same *ex-vivo* treatment with FucTVI.¹²⁶ When regulatory T cells are enzymatically treated with PNGaseF to partially remove N-glycans expressed on the surface, their capacity to suppress early activation events in the spleen is substantially impaired, leading to proliferation of naive and memory T cells (Table 3).¹¹⁸ Furthermore, pretreatment of cytotoxic T cells with either a *Clostridium perfringens* sialidase or an O-linked glycoprotein endopeptidase increased activation and cytolytic capacity *in vitro*, indicating that glycosylated surface proteins can hinder cytotoxic T cell activation and functioning (Table 3).¹¹⁹ More recently, a single-step chemoenzymatic approach for the development of antibody-cell conjugates was described. In this approach, the therapeutic T cell surface glycocalyx is *ex vivo* modified at LacNAc moieties with tumor-targeting antibodies. This is made possible by the use of a GDP-fucose analog, conjugated by click chemistry at the C6 position to a full length antibody, using *Helicobacter pylori* α -1,3-fucosyltransferase. In this way, T cells obtain specific tumor targeting capacity and resistance to inhibitory signals produced by tumor cells.¹¹⁶

Concluding remarks

Despite the clinical success of antibodies against immune checkpoints, only a subset of people exhibits sustained responses. This can be explained by the fact that anti-tumor immunity is influenced by a continuously evolving complex interplay of host, tumor and environmental factors governing the strength and timing of the anticancer response.

These factors combine to produce a ‘cancer-immune set point’, which can be seen as the equilibrium between the factors that promote or suppress anticancer immunity, that can predict responses to immunotherapy (for a review, see ref.¹²⁷). It is now clear that glycan structures and their binding proteins play very important roles in this.

Glyco-engineering of the tumor cell – immune cell interface thus provides exciting perspectives for improving immunotherapy in the future. Due to the complexity, species differences and




Figure 2. In this review, we discuss the role of different types of glycans decorating the surface of T cells, and their binding to GBPs and resulting functions. Central in the figure, several mammalian glycoforms that can occur on the T cell surface are shown. Above them, the GBPs that bind to them and the effects they have on T cells are outlined and below them we elaborate on the effects of therapeutic interventions on the glycan composition. The color of the arrows relates to the glycoforms, as indicated centrally in the figure, and the direction indicates decreased or increased expression of those glycoforms. The text next to the arrow then explains the effects on the T cell, resulting from the indicated changes in the glycoforms.

pleiotropic effects of manipulating this interface, the predictability of such glyco-engineering outcomes by extrapolation from *in vitro* or simple animal model systems will likely be low. It will inspire exciting research in glyco-oncology in models that are even more faithful representations of human disease, for many years to come. The first drugs that target glyco-components of the tumor-immune interface are in full clinical development, and it is likely that many more will follow.

Acknowledgments

This work was supported through a PhD fellowship to EDB from FWO, by VIB and UGhent institutional funding to NF, LM and NC.

Author contributions

EDB and NF reviewed the literature, wrote the text and made the tables. LM and NC carefully revised and co-wrote the manuscript. LM made Figure 1 and EDB made Figure 2.

Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

Abbreviations

ADCC	antibody-dependent cellular cytotoxicity
Asn	asparagine
ASGPR	Asialoglycoprotein receptor

CAR	chimeric antigen receptor
CD62E	E-selectin
CD62L	L-selectin
CD62P	P-selectin
CLR	C-type Lectin receptor
CRD	carbohydrate recognition domains
CRISPR-CAS	Clustered Regularly Interspaced Short Palindromic Repeats
CTLA-4	cytotoxic T-lymphocyte-associated antigen-4
DC	dendritic cell
DC-SIGN	dendritic cell-specific ICAM-grabbing non-integrin
DN	double negative
DP	double positive
ER	endoplasmic reticulum
Fut6	α 1-3 fucosyltransferase VI
Fut7	α 1-3 fucosyltransferase VII
GA	Golgi apparatus
GalNac	N-acetylgalactosamine
GBP	glycan-binding protein
Gcnt1	β 1-6 N-acetylglucosaminyltransferase-I
GlcNAc	N-acetylglucosamine
HCV	hepatitis C virus
ITIM	immunoreceptor tyrosine-based inhibition motif
LacNac	N-acetylglucosamine
Le _x	Lewis x antigen
Le _y	Lewis y antigen
MAG	myelin-associated glycoprotein
MBP	mannose-binding protein
MDSC	myeloid derived suppressor cell
Mgat5	β 1,6 N-acetylglucosaminyltransferase V
MGE	metabolic glycoengineering
MHC	major histocompatibility complex
MMR	macrophage mannose receptor
NSCLC	non-small cell lung cancer
OGT	O-GlcNAc transferase
PD-1	programmed cell death protein-1
PD-L1	programmed death ligand-1
PNA	peanut agglutinin
PSGL-1	P-selectin glycoprotein ligand-1
Siglec	sialic acid-binding immunoglobulin-type lectins
sLe ^x	sialyl-Lewis-X
SNA	<i>Sambucus nigra</i>
SSEA	stage-specific embryonic antigen 3
ST3Gal1	β -Galactoside α 2,3-Sialyltransferase 1
ST6Gal1	β -Galactoside α 2,6-Sialyltransferase 1
TALEN	Transcription Activator-Like Effector Nucleases
T _{CM}	central memory T cell
TCR	T cell receptor
T _{EM}	effector memory T cell
TIM	tumor-infiltrated macrophage
TIL	tumor-infiltrating lymphocyte
Treg	regulatory T cell

ORCID

Elien De Bousser  <http://orcid.org/0000-0002-4581-1312>

Leander Meuris  <http://orcid.org/0000-0001-8940-3022>

Nico Callewaert  <http://orcid.org/0000-0003-2069-6917>

Nele Festjens  <http://orcid.org/0000-0002-3429-5463>

References

- Cook KM, Hogg PJ. Post-translational control of protein function by disulfide bond cleavage. *Antioxid Redox Signal*. 2012;18:1987–2015. doi:10.1089/ars.2012.4807.
- Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell J. *Molecular cell biology*. 4th ed. New York, NY: W. H. Freeman; 2000. Section 17.6, Post-Translational Modifications and Quality Control in the Rough ER. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK21741/>
- Rogers LD, Overall CM. Proteolytic post-translational modification of proteins: proteomic tools and methodology. *Mol Cell Proteomics MCP*. 2013;12:3532–42. doi:10.1074/mcp.M113.031310.
- Moremen KW, Tiemeyer M, Nairn AV. Vertebrate protein glycosylation: diversity, synthesis and function. *Nat Rev Mol Cell Biol*. 2012;13:448–62. doi:10.1038/nrm3383.
- Neelamegham S, Mahal LK. Multi-level regulation of cellular glycosylation: from genes to transcript to enzyme to structure. *Curr Opin Struct Biol*. 2016;40:145–52. doi:10.1016/j.sbi.2016.09.013.
- Pothukuchi P, Agliarulo I, Russo D, Rizzo R, Russo F, Parashuraman S. Translation of genome to glycome: role of the Golgi apparatus. *FEBS Lett*. 2019;593:2390–411. doi:10.1002/feb2.v593.17.
- De Wachter C, Van Landuyt L, Callewaert N. Engineering of yeast glycoprotein expression. In: *Advances in Biochemical Engineering/Biotechnology*. Berlin, Heidelberg: Springer; 2018. p. 1–43. https://link.springer.com/chapter/10.1007/10_2018_69
- Nairn AV, York WS, Harris K, Hall EM, Pierce JM, Moremen KW. Regulation of glycan structures in animal tissues. *J Biol Chem*. 2008;283:17298–313. doi:10.1074/jbc.M801964200.
- Nairn AV, Aoki K, Dela Rosa M, Porterfield M, Lim J-M, Kulik M, Pierce JM, Wells L, Dalton S, Tiemeyer M, et al. Regulation of glycan structures in murine embryonic stem cells. *J Biol Chem*. 2012;287:37835–56. doi:10.1074/jbc.M112.405233.
- Spahn PN, Lewis NE. Systems glycobiology for glycoengineering. *Curr Opin Biotechnol*. 2014;30:218–24. doi:10.1016/j.copbio.2014.08.004.
- Liu G, Neelamegham S. Integration of systems glycobiology with bioinformatics toolboxes, glycoinformatics resources, and glyco-proteomics data. *Wiley Interdiscip Rev Syst Biol Med*. 2015;7:163–81. doi:10.1002/wsbm.2015.7.issue-4.
- Varki A. Biological roles of glycans. *Glycobiology*. 2017;27:3–49.
- Baum LG, Cobb BA. The direct and indirect effects of glycans on immune function. *Glycobiology*. 2017;27:619–24. doi:10.1093/glycob/cwx036.
- Thiemann S, Baum LG. Galectins and immune responses—just how do they do those things they do? *Annu Rev Immunol*. 2016;34:243–64. doi:10.1146/annurev-immunol-041015-055402.
- Horlacher T, Oberli MA, Werz DB, Kröck L, Bufali S, Mishra R, Sobek J, Simons K, Hirashima M, Niki T, et al. Determination of carbohydrate-binding preferences of human galectins with carbohydrate microarrays. *ChemBiochem Eur J Chem Biol*. 2010;11:1563–73. doi:10.1002/cbic.v11:11.
- Starr TK, Daniels MA, Lucido MM, Jameson SC, Hogquist KA. Thymocyte sensitivity and supramolecular activation cluster formation are developmentally regulated: a partial role for sialylation. *J Immunol*. 2003;171:4512–20. doi:10.4049/jimmunol.171.9.4512.
- Cummings RD. Structure and function of the selectin ligand PSGL-1. *Braz J Med Biol Res Rev Bras Pesqui Medicas E Biol*. 1999;32:519–28. doi:10.1590/S0100-879X1999000500004.
- Homeister JW, Thall AD, Petryniak B, Malý P, Rogers CE, Smith PL, Kelly RJ, Gersten KM, Askari SW, Cheng G, et al. The α (1,3)fucosyltransferases FucT-IV and FucT-VII exert collaborative control over selectin-dependent leukocyte recruitment and lymphocyte homing. *Immunity*. 2001;15:115–26. doi:10.1016/S1074-7613(01)00166-2.
- Sperandio M, Frommhold D, Babushkina I, Ellies LG, Olson TS, Smith ML, Fritzsche B, Pauly E, Smith DF, Nobiling R, et al. α 2,3-sialyltransferase-IV is essential for L-selectin ligand function in inflammation. *Eur J Immunol*. 2006;36:3207–15. doi:10.1002/eji.200636157.
- Pillai S, Netravali IA, Cariappa A, Mattoo H. Siglecs and immune regulation. *Annu Rev Immunol*. 2012;30:357–92. doi:10.1146/annurev-immunol-020711-075018.
- Swamy M, Pathak S, Grzes KM, Damerow S, Sinclair LV, van Aalten DMF, Cantrell DA. Glucose and glutamine fuel protein O-GlcNAcylation to control T cell self-renewal and malignancy. *Nat Immunol*. 2016;17:712–20. doi:10.1038/ni.3439.

22. Hewagama A, Gorelik G, Patel D, Liyanarachchi P, McCune WJ, Somers E, Gonzalez-Rivera T, Strickland F, Richardson B. Overexpression of X-Linked genes in T cells from women with lupus. *J Autoimmun.* 2013;41:60–71. doi:10.1016/j.jaut.2012.12.006.
23. Baum LG, Derbin K, Perillo NL, Wu T, Pang M, Uittenbogaart C. Characterization of terminal sialic acid linkages on human thymocytes. *J Biol Chem.* 1996;271:10793–99. doi:10.1074/jbc.271.18.10793.
24. Martin LT, Marth JD, Varki A, Varki NM. Genetically altered mice with different sialyltransferase deficiencies show tissue-specific alterations in sialylation and sialic acid 9-O-acetylation. *J Biol Chem.* 2002;277:32930–38. doi:10.1074/jbc.M203362200.
25. Moody AM, Chui D, Reche PA, Priatel JJ, Marth JD, Reinherz EL. Developmentally regulated glycosylation of the CD8 $\alpha\beta$ coreceptor stalk modulates ligand binding. *Cell.* 2001;107:501–12. doi:10.1016/S0092-8674(01)00577-3.
26. Daniels MA, Devine L, Miller JD, Moser JM, Lukacher AE, Altman JD, Kavathas P, Hogquist KA, Jameson SC. CD8 binding to MHC class I molecules is influenced by T cell maturation and glycosylation. *Immunity.* 2001;15:1051–61. doi:10.1016/S1074-7613(01)00252-7.
27. Moody AM, North SJ, Reinhold B, Dyken SJV, Rogers ME, Panico M, Dell A, Morris HR, Marth JD, Reinherz EL. Sialic acid capping of CD8 β core 1-O-glycans controls thymocyte-major histocompatibility complex class I interaction. *J Biol Chem.* 2003;278:7240–46. doi:10.1074/jbc.M210468200.
28. Pappu BP, Shrikant PA. Alteration of cell surface sialylation regulates antigen-induced naive CD8 $^{+}$ T cell responses. *J Immunol.* 2004;173:275–84. doi:10.4049/jimmunol.173.1.275.
29. Hobbs SJ, Nolz J. Regulation of T cell trafficking by enzymatic synthesis of O-glycans. *Front Immunol.* 2017;8:600. doi:10.3389/fimmu.2017.00600.
30. Aguilar AL, Gao Y, Hou X, Lauvau G, Yates JR, Wu P. Profiling of protein O-GlcNAcylation in murine CD8 $^{+}$ effector- and memory-like T cells. *ACS Chem Biol.* 2017;12:3031–38. doi:10.1021/acscchembio.7b00869.
31. Dennis JW, Lau KS, Demetriou M, Nabi IR. Adaptive regulation at the cell surface by N-Glycosylation. *Traffic.* 2009;10:1569–78. doi:10.1111/tra.2009.10.issue-11.
32. Earl LA, Bi S, Baum LG. N- and O-Glycans Modulate Galectin-1 Binding, CD45 Signaling, and T Cell Death. *J Biol Chem.* 2010;285:2232–44. doi:10.1074/jbc.M109.066191.
33. Morgan R, Gao G, Pawling J, Dennis JW, Demetriou M, Li B. N-acetylglucosaminyltransferase V (Mgat5)-mediated N-glycosylation negatively regulates Th1 cytokine production by T cells. *J Immunol Baltim Md 1950.* 2004;173:7200–08.
34. Lau KS, Partridge EA, Grigorian A, Silvescu CI, Reinhold VN, Demetriou M, Dennis JW. Complex N-Glycan Number and Degree of Branching Cooperate to Regulate Cell Proliferation and Differentiation. *Cell.* 2007;129:123–34. doi:10.1016/j.cell.2007.01.049.
35. Grigorian A, Torossian S, Demetriou M. T-cell growth, cell surface organization, and the galectin glycoprotein lattice. *Immunol Rev.* 2009;230:232–46. doi:10.1111/imr.2009.230.issue-1.
36. Chen H-L, Li CF, Grigorian A, Tian W, Demetriou M. T cell receptor signaling co-regulates multiple golgi genes to enhance N-glycan branching. *J Biol Chem.* 2009;284:32454–61. doi:10.1074/jbc.M109.023630.
37. Zhang W, Wearsch PA, Zhu Y, Leonhardt RM, Cresswell P. A role for UDP-glucose glycoprotein glucosyltransferase in expression and quality control of MHC class I molecules. *Proc Natl Acad Sci U S A.* 2011;108:4956–61. doi:10.1073/pnas.1102527108.
38. Wearsch PA, Peaper DR, Cresswell P. Essential glycan-dependent interactions optimize MHC class I peptide loading. *Proc Natl Acad Sci.* 2011;108:4950–55. doi:10.1073/pnas.1102524108.
39. Ryan SO, Cobb BA. Host glycans and antigen presentation. *Microbes Infect Inst Pasteur.* 2012;14:894–903. doi:10.1016/j.micinf.2012.04.010.
40. Ryan SO, Cobb BA. Roles for major histocompatibility complex glycosylation in immune function. *Semin Immunopathol.* 2012;34:425–41. doi:10.1007/s00281-012-0309-9.
41. Swiedler SJ, Freed JH, Tarentino AL, Plummer TH, Hart GW. Oligosaccharide microheterogeneity of the murine major histocompatibility antigens. Reproducible site-specific patterns of sialylation and branching in asparagine-linked oligosaccharides. *J Biol Chem.* 1985;260:4046–54.
42. Ryan SO, Bonomo JA, Zhao F, Cobb BA. MHCII glycosylation modulates *Bacteroides fragilis* carbohydrate antigen presentation. *J Exp Med.* 2011;208:1041–53. doi:10.1084/jem.20100508.
43. Cobb BA, Kasper DL. Characteristics of carbohydrate antigen binding to the presentation protein HLA-DR. *Glycobiology.* 2008;18:707–18. doi:10.1093/glycob/cwn050.
44. Johnson JL, Jones MB, Ryan SO, Cobb BA. The Regulatory Power of Glycans and their Binding Partners in Immunity. *Trends Immunol.* 2013;34:290–98. doi:10.1016/j.it.2013.01.006.
45. Amano M, Galvan M, He J, Baum LG. The ST6Gal I Sialyltransferase selectively modifies N-Glycans on CD45 to negatively regulate galectin-1-induced CD45 clustering, phosphatase modulation, and T cell death. *J Biol Chem.* 2003;278:7469–75. doi:10.1074/jbc.M209595200.
46. Araujo L, Khim P, Mkhikian H, Mortales C-L, Demetriou M. Glycolysis and glutaminolysis cooperatively control T cell function by limiting metabolite supply to N-glycosylation. *eLife.* 2017;6. doi:10.7554/eLife.21330.
47. Hauser MA, Kindinger I, Laufer JM, Späte A-K, Bucher D, Vanes SL, Krueger WA, Wittmann V, Legler DF. Distinct CCR7 glycosylation pattern shapes receptor signaling and endocytosis to modulate chemotactic responses. *J Leukoc Biol.* 2016;99:993–1007. doi:10.1189/jlb.2VMA0915-432RR.
48. Rossi FMV, Corbel SY, Merzaban JS, Carlow DA, Gossens K, Duenas J, So L, Yi L, Ziltener HJ. Recruitment of adult thymic progenitors is regulated by P-selectin and its ligand PSGL-1. *Nat Immunol.* 2005;6:626–34. doi:10.1038/ni1203.
49. Sultana DA, Zhang SL, Todd SP, Bhandoola A. Expression of functional PSGL-1 on hematopoietic progenitors is developmentally regulated. *J Immunol Baltim Md 1950.* 2012;188:4385–93.
50. Li Y, Xie M, Men L, Du J. O-GlcNAcylation in immunity and inflammation: an intricate system (Review). *Int J Mol Med.* 2019;44:363–74. doi:10.3892/ijmm.2019.4238.
51. Daniels MA, Hogquist KA, Jameson SC. Sweet “n” sour: the impact of differential glycosylation on T cell responses. *Nat Immunol.* 2002;3:903–10. doi:10.1038/ni1002-903.
52. Demetriou M, Granovsky M, Quaggin S, Dennis JW. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. *Nature.* 2001;409:733. doi:10.1038/35055582.
53. Smith LK, Boukhalel GM, Condotta SA, Mazouz S, Guthmiller JJ, Vijay R, Butler NS, Bruneau J, Shoukry NH, Krawczyk CM, et al. Interleukin-10 Directly Inhibits CD8 $^{+}$ T Cell Function by Enhancing N-Glycan Branching to Decrease Antigen Sensitivity. *Immunity.* 2018;48:299–312.e5. doi:10.1016/j.immuni.2018.01.006.
54. An HJ, Froehlich JW, Lebrilla CB. Determination of glycosylation sites and site-specific heterogeneity in glycoproteins. *Curr Opin Chem Biol.* 2009;13:421–26. doi:10.1016/j.cbpa.2009.07.022.
55. Clark MC, Baum LG. T cells modulate glycans on CD43 and CD45 during development and activation, signal regulation, and survival. *Ann N Y Acad Sci.* 2012;1253:58–67. doi:10.1111/j.1749-6632.2011.06304.x.
56. Golks A, Tran -T-T, Goetschy JF, Guerini D. Requirement for O-linked N-acetylglucosaminyltransferase in lymphocyte activation. *Embo J.* 2007;26:4368–79. doi:10.1038/sj.emboj.7601845.
57. Ramakrishnan P, Clark PM, Mason DE, Peters EC, Hsieh-Wilson LC, Baltimore D. Activation of the Transcriptional Function of the NF- κ B Protein c-Rel by O-GlcNAc Glycosylation. *Sci Signal.* 2013;6:ra75. doi:10.1126/scisignal.2004097.
58. McEver RP. Selectin-carbohydrate interactions during inflammation and metastasis. *Glycoconj J.* 1997;14:585–91. doi:10.1023/A:1018584425879.

59. Borsig L. Selectins in cancer immunity. *Glycobiology*. 2018;28:648–55. doi:10.1093/glycob/cwx105.
60. Häselmann I, Borsig L. Altered tumor-cell glycosylation promotes metastasis. *Front Oncol*. 2014;4:28. doi:10.3389/fonc.2014.00028.
61. Rodríguez E, Schetters STT, van Kooyk Y. The tumour glyco-code as a novel immune checkpoint for immunotherapy. *Nat Rev Immunol*. 2018;18:204–11. doi:10.1038/nri.2018.3.
62. Peixoto A, Relvas-Santos M, Azevedo R, Santos LL, Ferreira JA. Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks. *Front Oncol*. 2019;9:380–380. doi:10.3389/fonc.2019.00380.
63. Li C-W, Lim S-O, Xia W, Lee -H-H, Chan L-C, Kuo C-W, Khoo K-H, Chang -S-S, Cha J-H, Kim T, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. *Nat Commun*. 2016;7:12632. doi:10.1038/ncomms12632.
64. Li C-W, Lim S-O, Chung EM, Kim Y-S, Park AH, Yao J, Cha J-H, Xia W, Chan L-C, Kim T, et al. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. *Cancer Cell*. 2018;33:187–201.e10. doi:10.1016/j.ccell.2018.01.009.
65. Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. *Nat Rev Immunol*. 2001;1:220–28. doi:10.1038/35105024.
66. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB, Kuchroo VK. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. *Nat Immunol*. 2005;6:1245–52. doi:10.1038/nri1271.
67. Wang H, Kaur G, Sankin AI, Chen F, Guan F, Zang X. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. *J Hematol Oncol*. 2019;12:59. doi:10.1186/s13045-019-0746-1.
68. Sundblad V, Morosi LG, Geffner JR, Rabinovich GA. Galectin-1: A Jack-of-All-Trades in the Resolution of Acute and Chronic Inflammation. *J Immunol*. 2017;199:3721–30. doi:10.4049/jimmunol.1701172.
69. Clemente T, Vieira NJ, Cerliani JP, Adrain C, Luthi A, Dominguez MR, Yon M, Barence FC, Riul TB, Cummings RD, et al. Proteomic and functional analysis identifies galectin-1 as a novel regulatory component of the cytotoxic granule machinery. *Cell Death Dis*. 2017;8:e3176. doi:10.1038/cddis.2017.506.
70. Yu F, Finley RL, Raz A, Kim H-RC. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. *J Biol Chem*. 2002;277:15819–27. doi:10.1074/jbc.M200154200.
71. Kouo T, Huang L, Pucsek AB, Cao M, Solt S, Armstrong T, Jaffee E. Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells. *Cancer Immunol Res*. 2015;3:412–23. doi:10.1158/2326-6066.CIR-14-0150.
72. Stillman BN, Hsu DK, Pang M, Brewer CF, Johnson P, Liu F-T, Baum LG. Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. *J Immunol Baltim Md* 1950. 2006;176:778–89.
73. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. *Cancer Immunol Immunother CII*. 2010;59:1593–600. doi:10.1007/s00262-010-0855-8.
74. Lafouresse F, Bellard E, Laurent C, Moussion C, J-J F, Ysebaert L, Girard J-P. L-selectin controls trafficking of chronic lymphocytic leukemia cells in lymph node high endothelial venules in vivo. *Blood*. 2015;126:1336–45. doi:10.1182/blood-2015-02-626291.
75. Stanczak MA, Siddiqui SS, Trefny MP, Thommen DS, Boligan KF, von GS, Tzankov A, Tietze L, Lardinois D, Heinzelmann-Schwarz V, et al. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. *J Clin Invest*. 2018;128:4912–23. doi:10.1172/JCI120612.
76. Haas Q, Boligan KF, Jandus C, Schneider C, Simillion C, Stanczak MA, Haubitz M, Jafari SMS, Zippelius A, Baerlocher GM, et al. Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment. *Cancer Immunol Res*. 2019;7:707–18. doi:10.1158/2326-6066.CIR-18-0505.
77. Wang J, Sun J, Liu LN, Flies DB, Nie X, Toki M, Zhang J, Song C, Zarr M, Zhou X, et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. *Nat Med*. 2019;25:656–66. doi:10.1038/s41591-019-0374-x.
78. Limagne E, Richard C, Thibaudin M, Fumet J-D, Truntzer C, Lagrange A, Favier L, Coudert B, Ghiringhelli F. Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients. *Oncimmunology*. 2019;8:e1564505. doi:10.1080/2162402X.2018.1564505.
79. Gonçalves Silva I, Yasinska IM, Sakhnevych SS, Fiedler W, Wellbrock J, Bardelli M, Varani L, Hussain R, Siligardi G, Ceccone G, et al. The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells. *EBioMedicine*. 2017;22:44–57. doi:10.1016/j.ebiom.2017.07.018.
80. Wdowiak K, Gallego-Colon E, Francuz T, Czajka-Francuz P, Ruiz-Agamez N, Kubeczko M, Grochoła I, Wybraniec MT, Chudek J, Wojnar J. Increased serum levels of Galectin-9 in patients with chronic lymphocytic leukemia. *Oncol Lett*. 2019;17:1019–29. doi:10.3892/ol.2018.9656.
81. Zheng Y, Feng W, Wang Y-J, Sun Y, Shi G, Yu Q. Galectins as potential emerging key targets in different types of leukemia. *Eur J Pharmacol*. 2019;844:73–78. doi:10.1016/j.ejphar.2018.11.019.
82. Zhu J, Zheng Y, Zhang H, Liu Y, Sun H, Zhang P. Galectin-1 induces metastasis and epithelial-mesenchymal transition (EMT) in human ovarian cancer cells via activation of the MAPK JNK/p38 signalling pathway. *Am J Transl Res*. 2019;11:3862–78.
83. Goud NS, Soukya PSL, Ghouse M, Komal D, Alvala R, Alvala M. Human Galectin-1 and its inhibitors: privileged target for cancer and HIV. *Mini Rev Med Chem*. 2019;19:1369–78. doi:10.2174/1389557519666190304120821.
84. Chen H-Y, Fermin A, Vardhana S, Weng I-C, Lo KFR, Chang E-Y, Maverakis E, Yang R-Y, Hsu DK, Dustin ML, et al. Galectin-3 negatively regulates TCR-mediated CD4+ T-cell activation at the immunological synapse. *Proc Natl Acad Sci U S A*. 2009;106:14496–501. doi:10.1073/pnas.0903497106.
85. Kaur M, Kumar D, Butty V, Singh S, Esteban A, Fink GR, Ploegh HL, Sehrawat S. Galectin-3 Regulates γ -Herpesvirus Specific CD8 T Cell Immunity. *iScience*. 2018;9:101–19. doi:10.1016/j.isci.2018.10.013.
86. Polonskaya Z, Deng S, Sarkar A, Kain L, Comellas-Aragones M, McKay CS, Kaczanowska K, Holt M, McBride R, Palomo V, et al. T cells control the generation of nanomolar-affinity anti-glycan antibodies. *J Clin Invest*. 2017;127:1491–504. doi:10.1172/JCI91192.
87. Li RE, van Vliet SJ, van Kooyk Y. Using the glycan toolbox for pathogenic interventions and glycan immunotherapy. *Curr Opin Biotechnol*. 2018;51:24–31. doi:10.1016/j.copbio.2017.11.003.
88. Danishefsky SJ, Shue Y-K, Chang MN, Wong C-H. Development of Globo-H cancer vaccine. *Acc Chem Res*. 2015;48:643–52. doi:10.1021/ar5004187.
89. Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects - Tabular View - ClinicalTrials.gov; <https://clinicaltrials.gov/ct2/show/record/NCT02310464>
90. Steentoft C, Miglioni D, King TR, Mandel U, June CH, Posey AD. Glycan-directed CAR-T cells. *Glycobiology*. 2018;28:656–69. doi:10.1093/glycob/cwy008.
91. Mereiter S, Balmaña M, Campos D, Gomes J, Reis CA. Glycosylation in the Era of Cancer-Targeted Therapy: where Are We Heading?. *Cancer Cell*. 2019;36:6–16. doi:10.1016/j.ccell.2019.06.006.
92. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer*. 2012;12:252–64. doi:10.1038/nrc3239.
93. Van Cutsem E, Köhne C-H, Hitre E, Zaluski J, Chang Chien C-R, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, et al. Cetuximab and chemotherapy as initial treatment for metastatic

- colorectal cancer. *N Engl J Med.* 2009;360:1408–17. doi:10.1056/NEJMoa0805019.
94. Lee HT, Lee SH, Heo Y-S. Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology. *Molecules.* 2019;24:1190.
 95. Munkley J, Scott E. Targeting Aberrant Sialylation to Treat Cancer. *Medicines.* 2019;6:102. doi:10.3390/medicines6040102.
 96. Fraschilla I, Pillai S. Viewing Siglecs through the lens of tumor immunology. *Immunol Rev.* 2017;276:178–91. doi:10.1111/imr.2017.276.issue-1.
 97. A safety and tolerability study of NC318 in subjects with advanced or metastatic solid tumors - Full Text View - clinicalTrials.gov [Internet]; [accessed 2019 Sep 18]. <https://clinicaltrials.gov/ct2/show/NCT03665285>
 98. Ren X. Immunosuppressive checkpoint Siglec-15: a vital new piece of the cancer immunotherapy jigsaw puzzle. *Cancer Biol Med.* 2019;16:205–10. doi:10.20892/j.issn.2095-3941.2018.0141.
 99. Natoni A, Macauley MS, O'Dwyer ME. Targeting Selectins and Their Ligands in Cancer. *Front Oncol.* 2016;6:93. doi:10.3389/fonc.2016.00093.
 100. Chou F-C, Chen H-Y, Kuo -C-C, Sytwu H-K. Role of Galectins in Tumors and in Clinical Immunotherapy. *Int J Mol Sci.* 2018;19. doi:10.3390/ijms19020430.
 101. He Y, Cao J, Zhao C, Li X, Zhou C, Hirsch FR. TIM-3, a promising target for cancer immunotherapy. *Onco Targets Ther.* 2018;11:7005–09. doi:10.2147/OTT.
 102. Van Landuyt L, Lonigro C, Meuris L, Callewaert N. Customized protein glycosylation to improve biopharmaceutical function and targeting. *Curr Opin Biotechnol.* 2019;60:17–28. doi:10.1016/j.copbio.2018.11.017.
 103. Buettner MJ, Shah SR, Saeui CT, Ariss R, Yarema KJ. Improving Immunotherapy Through Glycodesign. *Front Immunol.* 2018;9:2485.
 104. Nemudryi AA, Valetdinova KR, Medvedev SP, Zakian SM. TALEN and CRISPR/Cas Genome Editing Systems: tools of Discovery. *Acta Naturae.* 2014;6:19–40. doi:10.32607/20758251-2014-6-3-19-40.
 105. Gupta RM, Musunuru K. Expanding the genetic editing tool kit: zFNs, TALENs, and CRISPR-Cas9. *J Clin Invest.* 2014;124:4154–61. doi:10.1172/JCI72992.
 106. Komor AC, Badran AH, Liu DR. CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes. *Cell.* 2017;169:559. doi:10.1016/j.cell.2017.04.005.
 107. Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, Chen PJ, Wilson C, Newby GA, Raguram A, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. *Nature.* 2019;576:149–57. doi:10.1038/s41586-019-1711-4.
 108. Kuball J, Hauptrock B, Malina V, Antunes E, Voss R-H, Wolf M, Strong R, Theobald M, Greenberg PD. Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain. *J Exp Med.* 2009;206:463–75. doi:10.1084/jem.20082487.
 109. Okada M, Chikuma S, Kondo T, Hibino S, Machiyama H, Yokosuka T, Nakano M, Yoshimura A. Blockage of Core Fucosylation Reduces Cell-Surface Expression of PD-1 and Promotes Anti-tumor Immune Responses of T Cells. *Cell Rep.* 2017;20:1017–28. doi:10.1016/j.celrep.2017.07.027.
 110. Cedeno-Laurent F, Opperman M, Barthel SR, Hays D, Schatton T, Zhan Q, He X, Matta KL, Supko JG, Frank MH, et al. Metabolic inhibition of galectin-1-binding carbohydrates accentuates anti-tumor immunity. *J Invest Dermatol.* 2012;132:410–20. doi:10.1038/jid.2011.335.
 111. Ito K, Scott SA, Cutler S, Dong L-F, Neuzil J, Blanchard H, Ralph SJ. Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress. *Angiogenesis.* 2011;14:293–307. doi:10.1007/s10456-011-9213-5.
 112. Rillahan CD, Antonopoulos A, Lefort CT, Sonon R, Azadi P, Ley K, Dell A, Haslam SM, Paulson JC. Global Metabolic Inhibitors of Sialyl- and Fucosyltransferases. *Nat Chem Biol.* 2012;8:661–68. doi:10.1038/nchembio.999.
 113. Büll C, Boltje TJ, Balnegger N, Weischer SM, Wassink M, Gemst JJV, Bloemendal VRLJ, Boon L, Vlag JVD, Heise T, et al. Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell-Mediated Tumor Immunity. *Cancer Res.* 2018;78:3574–88. doi:10.1158/0008-5472.CAN-17-3376.
 114. Dias AM, Correia A, Pereira MS, Almeida CR, Alves I, Pinto V, Catarino TA, Mendes N, Leander M, Oliva-Teles MT, et al. Metabolic control of T cell immune response through glycans in inflammatory bowel disease. *Proc Natl Acad Sci.* 2018; 115:E4651–60. doi:10.1073/pnas.1720409115.
 115. Zheng T, Jiang H, Gros M, Del Amo DS, Sundaram S, Lauvau G, Marlow F, Liu Y, Stanley P, Wu P. Tracking N-acetylglucosamine on cell-surface glycans in vivo. *Angew Chem Int Ed Engl.* 2011;50:4113–18. doi:10.1002/anie.v50.18.
 116. Li J, Chen M, Liu Z, Zhang L, Felding BH, Moremen KW, Lauvau G, Abadier M, Ley K, Wu P. A Single-Step Chemoenzymatic Reaction for the Construction of Antibody-Cell Conjugates. *ACS Cent Sci.* 2018;4:1633–41. doi:10.1021/acscentsci.8b00552.
 117. Parmar S, Liu X, Najjar A, Shah N, Yang H, Yvon E, Rezvani K, McNiece I, Zweidler-McKay P, Miller L, et al. Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo. *Blood.* 2015;125:1502–06. doi:10.1182/blood-2014-10-603449.
 118. Cabral J, Hanley SA, Gerlach JQ, O'Leary N, Cunningham S, Ritter T, Ceredig R, Joshi L, Griffin MD. Distinctive Surface Glycosylation Patterns Associated With Mouse and Human CD4⁺ Regulatory T Cells and Their Suppressive Function. *Front Immunol.* 2017;8:987. doi:10.3389/fimmu.2017.00987.
 119. Sadighi Akha AA, Berger SB, Miller RA. Enhancement of CD8 T-cell function through modifying surface glycoproteins in young and old mice. *Immunology.* 2006;119:187–94. doi:10.1111/imm.2006.119.issue-2.
 120. Yoon HY, Koo H, Kim K, Kwon IC. Molecular imaging based on metabolic glycoengineering and bioorthogonal click chemistry. *Biomaterials.* 2017;132:28–36. doi:10.1016/j.biomaterials.2017.04.003.
 121. Büll C, Boltje TJ, Wassink M, de Graaf AMA, van Delft FL, den Brok MH, Adema GJ. Targeting aberrant sialylation in cancer cells using a fluorinated sialic acid analog impairs adhesion, migration, and in vivo tumor growth. *Mol Cancer Ther.* 2013;12:1935–46. doi:10.1158/1535-7163.MCT-13-0279.
 122. Varki A, Gagneux P. Multifarious roles of sialic acids in immunity. *Ann N Y Acad Sci.* 2012;1253:16–36. doi:10.1111/j.1749-6632.2012.06517.x.
 123. Büll C, Heise T, van Hilten N, Pijnenborg JFA, Bloemendal VRLJ, Gerrits L, Kers-Rebel ED, Ritschel T, den Brok MH, Adema GJ, et al. Steering Siglec-Sialic Acid Interactions on Living Cells using Bioorthogonal Chemistry. *Angew Chem Int Ed Engl.* 2017;56:3309–13. doi:10.1002/anie.201612193.
 124. Pan H, Li P, Li G, Li W, Hu B, He H, Chen Z, Wang F, Liu L, Gong Y, et al. Glycometabolic Bioorthogonal Chemistry-Guided Viral Transduction for Robust Human T Cell Engineering. *Adv Funct Mater.* 2019;29:1807528. doi:10.1002/adfm.v29.22.
 125. Hong S, Shi Y, Wu NC, Grande G, Douthit L, Wang H, Zhou W, Sharpless KB, Wilson IA, Xie J, et al. Bacterial glycosyltransferase-mediated cell-surface chemoenzymatic glycan modification. *Nat Commun.* 2019;10:1–11. doi:10.1038/s41467-019-09608-w.
 126. Mondal N, Silva M, Castano AP, Maus MV, Sackstein R. Glycoengineering of chimeric antigen receptor (CAR) T-cells to enforce E-selectin binding. *J Biol Chem.* 2019;294:18465–74. doi:10.1074/jbc.RA119.011134.
 127. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. *Nature.* 2017;541:321–30. doi:10.1038/nature21349.